Keri Arnold

Keri Arnold is a trial attorney with over twenty years’ experience defending companies in product liability, environmental, and complex commercial litigation. She has tried over a dozen cases to verdict, including seven as first-chair trial counsel, on behalf of major pharmaceutical, tobacco, and energy companies. Keri has supervised the management and discovery of mass actions pending in state and federal courts and has extensive experience developing complex medical and scientific evidence for presentation at trial.

Most recently, Keri was a member of the trial team that secured a groundbreaking victory for Microsoft, defeating the FTC’s efforts to enjoin its $68.7 billion acquisition of Activision Blizzard and winning the second-biggest merger trial in American history. Following a five-day bench trial, Judge Jacqueline Scott Corley denied the FTC’s motion for preliminary injunction, finding that the FTC failed to make its case that the acquisition would substantially lessen competition in the gaming industry.

Keri also recently represented a major chemical manufacturer in the Aqueous Film-Forming Foams (AFFF) Products Liability Litigation in the District of South Carolina. The litigation, involving alleged PFAS groundwater contamination from the use of AFFF, is considered the most significant PFAS litigation in the country. Keri was set to serve as a member of the trial team for the manufacturer in the first bellwether trial in the AFFF MDL, which was halted on the eve of trial when the remaining parties announced a settlement to end all water-provider claims brought against the manufacturer. Keri also currently represents Monsanto in litigation arising out of claims that its popular herbicide Roundup causes non-Hodgkin lymphoma.

Before joining Wilkinson Stekloff, Keri was a partner at Arnold & Porter, where she specialized in trial work and product liability litigation. Keri is a Fellow of the American College of Trial Lawyers and has been a Lecturer in Law at Columbia Law School. She is nationally ranked by Chambers and Partners in Products Liability and Mass Torts, and by Legal 500 for “Product Liability and Mass Tort Defense,” including “Toxic Tort” and “Pharmaceuticals and Medical Devices.” Keri has been recognized by Benchmark as a “Litigation Star” and named to their list of the “Top 250 Women in Litigation.” Keri has also appeared on Lawdragon’s list of the “500 Leading Litigators in America,” and was named one of among the 2025 Notable Litigators & Trial Lawyers by Crain’s New York Business.